Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926793 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
A Phase 1 study, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03926793: Completed Phase 1 study, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
NCT03926793 is a Phase 1 study that has completed, run by GB002, Inc., a wholly owned subsidiary of Gossamer Bio. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03926793, a Phase 1 study, has completed, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled, multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH).
Primary Outcome
To evaluate the safety and tolerability of GB002
Interventions
- DRUG Placebo
- DEVICE Generic Dry Powder Inhaler
- DRUG GB002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-02-04 |
| Est. Completion | 2021-05-05 |
| Phase | Phase 1 |
What the finished NCT03926793 record still lists
NCT03926793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03926793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03926793 about?
NCT03926793 is a clinical study titled "Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension". This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled, multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1 Pulmonary Arterial Hyper...
What is the current status of trial NCT03926793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-02-04. Estimated completion is 2021-05-05.
What interventions are being tested in trial NCT03926793?
The interventions under investigation include: Placebo (DRUG), Generic Dry Powder Inhaler (DEVICE), GB002 (DRUG).
Who is sponsoring clinical trial NCT03926793?
This trial is sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03926793's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI